GlycoScoreDx has developed the GlycoScore Prostate Cancer Test, a blood test that utilizes a unique combination of glycan biomarkers to accurately identify clinically significant prostate cancer while ruling out the disease in many cases. This technology reduces the need for invasive prostate-tissue biopsies, addressing the high rate of false positives and negatives associated with traditional PSA testing.
Funding
$870K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current prostate cancer diagnostic methods, which rely on detecting prostate-specific antigen (PSA) levels in blood, often lead to false positives and negatives. This results in many men undergoing unnecessary and invasive prostate-tissue biopsies, which can be painful and carry a risk of infection, while a significant number of patients with prostate cancer are not diagnosed due to false negative results. There is a need for more accurate diagnostic tests that can be applied earlier in the clinical pathway.
Solution
GlycoScoreDx has developed the GlycoScore Prostate Cancer Test, a blood test that utilizes a unique combination of glycan biomarkers to accurately identify clinically significant prostate cancer. The test aims to reduce the number of unnecessary biopsies by ruling out cancer in many cases, ensuring that only patients with a clinically significant risk of the disease need to undergo the invasive procedure of prostate-tissue biopsy. The GlycoScore test is designed to be easily adoptable by any pathology laboratory and can be performed using existing infrastructure, providing easy-to-interpret results with a fast turnaround time.
Target Audience
The primary target audience includes pathology laboratories and clinicians involved in prostate cancer diagnosis, particularly urologists and oncologists.
Features
- Utilizes a unique combination of glycan biomarkers for prostate cancer detection.
- Designed to be easily adoptable by any pathology laboratory.
- Can be performed using existing laboratory infrastructure.
- Provides easy-to-interpret results.
- Offers a fast turnaround time.
- Based on over a decade of clinical and academic research.
- Aims to differentiate between clinically significant prostate cancer and slow-growing cancer.